Development of a 4-valent genotyping assay for direct identification of the most frequent Pseudomonas aeruginosa serotypes from respiratory specimens of pneumonia patients
| Autor: | Holger Koch, Marianne Wyss, Sandra Jampen, Hedvika Lazar, Michael P. Rudolf, Thomas Emrich, Verena Gafner |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Microbiology (medical) Serotype Microbiological culture Genotype Context (language use) Biology Real-Time Polymerase Chain Reaction medicine.disease_cause Sensitivity and Specificity Microbiology Pneumonia Bacterial medicine Humans Pseudomonas Infections Genotyping Bacteriological Techniques Pseudomonas aeruginosa Reproducibility of Results General Medicine medicine.disease Virology Pneumonia Molecular Diagnostic Techniques Panobacumab |
| Zdroj: | Journal of Medical Microbiology. 63:508-517 |
| ISSN: | 1473-5644 0022-2615 |
| DOI: | 10.1099/jmm.0.066043-0 |
| Popis: | Pseudomonas aeruginosa is a common cause of nosocomial infections and is associated with high rates of mortality. In order to facilitate rapid and sensitive identification of the most prevalent serotypes of P. aeruginosa, we have developed a 4-valent real-time PCR-based assay using oligonucleotides specific for open-reading frames constituting the O-antigen-specific lipopolysaccharide loci of P. aeruginosa. The assay simultaneously detects and differentiates between each of the four serotypes IATS-O1, -O6, -O11 and serogroup 2 (IATS-O2, -O5, and -O16) with high sensitivity and specificity in a single-tube reaction. No cross-reactivity was observed with other serotypes of P. aeruginosa or other microbial species, and reproducibility was demonstrated regardless of template, i.e. purified DNA, bacterial culture and clinical specimens (broncho-alveolar lavage). The limit of detection of the assay was approximately 100 copies per reaction for IATS-O1, -O2 and -O11, and 50 copies per reaction for IATS-O6. Comparison of the assay specificity with a commercially available slide agglutination kit showed consistent results; however, the number of non-typable isolates was reduced by 15 % using the genotyping assay. Use of the 4-valent genotyping assay in the context of a clinical trial resulted in identification of pneumonia patients positive for the IATS-O11 serotype, and hence eligible for therapy with panobacumab (an investigational monoclonal antibody against the O-polysaccharide of serotype IATS-O11). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|